Clinical Trial: An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer

U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07589569) titled 'An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer' on May 09.

Brief Summary: This is a multicenter, open-label, single-arm, phase II cilinical trial designed to evaluate the efficacy and safety of the KRAS G12C selective inhibitor HRS-7058 in patients with KRAS G12C-mutated advanced pancreatic cancer who had failed 1-2 lines of previous systemic therapy.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Pancreatic Cancer

Intervention: DRUG: HRS-7058

HRS-7058

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shandong Suncadia Medicine Co., Ltd.

Published...